Bioage Labs Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bioage Labs Inc 's ROA in the second quarter of 2026?
Bioage Labs Inc recorded a cumulative net loss of $-94 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -27.05%.

However, within the Healthcare sector 402 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3590, from total ROA ranking in the first quarter of 2026 at 4178.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	24.52 %	16.36 %	-17.68 %	-9.65 %	1301.6 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-94	-90	-81	-76	-79
Return On Assets (TTM)	-27.05 %	-27.28 %	-25.54 %	-22.87 %	-23.27 %
BIOA's Total Ranking	# 3590	# 4178	# 3604	# 3650	# 3783
Total Assets (TTM) in million	399	398	295	305	321
Seq. Total Assets Change	0.42 %	34.84 %	-3.25 %	-4.95 %	-6.16 %
Seq. Net Income Change	-	-	-	-	-

BIOA's 5 Years Annual ROA >> Back to BIOA Management Effectiveness >> Compare BIOA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 151
Sector	# 403
Overall	# 3554

Return On Assets Statistics
High	Average	Low
29.92 %	-8.59 %	-78.1 %
(Jun 30 2014)		(Dec 31 2017)

Financial Statements
Bioage Labs Inc 's Assets	$ 399 million	BIOA's Balance sheet
Bioage Labs Inc 's Income	$ -26 million	Quarterly BIOA's Income Statement
BIOA's Income by Division		See BIOA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2017) FY 2017	(Dec 31 2016) FY 2016	(Dec 31 2015) FY 2015
Y / Y Total Assets Change	-17.68 %	415.49 %	-56.91 %	12.75 %	-6.14 %
Total Assets in million	295	358	70	161	143
Y / Y Net Income Change	-	-	-	-	-12.95 %
Net Income in million	-81	-71	-102	-28	41
Annual Return On Assets	-27.32 %	-19.84 %	-147 %	-17.59 %	28.77 %

BIOA's 5 Years Annual ROA >> Back to BIOA Management Effectiveness >> Compare BIOA ROA to its Competitors

More Return On Assets Ratios
BIOA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BIOA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BIOA's Competitors
Subscribers only: Roa for Bioage Labs Inc 's Suppliers
Subscribers only: Return On Assets for BIOA's Customers

You may also want to know
BIOA's Roi	BIOA's Inventory Turnover Ratio	BIOA's Growth Rates	BIOA's Dividend Comparisons
	BIOA's Profitability Ratios	BIOA's Asset Turnover Ratio	BIOA's Dividend Growth
BIOA's Roe	BIOA's Valuation Ratios	BIOA's Financial Strength Ratios	BIOA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-10T09:28:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.